Prostacyclin therapy for pulmonary arterial hypertension

Texas Heart Institute Journal

Volumn 37, Issue 4, 2010, Pages 391-399

  Ruan, Cheng Huai ^a   Dixon, Richard A F ^b   Willerson, James T ^b   Ruan, Ke He ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antihypertensive agents; Asodilator agents; Cell therapy; Endothelin antagonists Inhibitors; Gene therapy; Genetic predisposition to disease; Hypertension; Hypertrophy; Monocrotaline; Prostacyclin; Prostacyclin synthetase; Pulmonary artery physio pathology; Pulmonary classification drug therapy etiology genetics; Receptors; Right ventricular; Vascular diseases drug therapy

Indexed keywords

ADENOSINE; ADENOVIRUS VECTOR; ARACHIDONIC ACID; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYGEN; PARVOVIRUS VECTOR; PHOSPHODIESTERASE III/IV INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTEIN P21; RETINOIC ACID; SILDENAFIL; SODIUM CHLORIDE; TOLAFENTRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ADD ON THERAPY; ARTERY CONSTRICTION; CELL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; GENE THERAPY; HEADACHE; HEART CONTRACTION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOXEMIA; MORTALITY; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; STEM CELL TRANSPLANTATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; EPOPROSTENOL; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY; INTRAMOLECULAR OXIDOREDUCTASES; PULMONARY ARTERY; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77957348624     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43-54.
2. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, et al. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 2009; 119(17): 2313-22.
3. Burger CD. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD 2009;6(2):137-44.
4. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53(17):1573-619.
5. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association [published erratum appears in Circulation 2009;120(2):e13]. Circulation 2009;119(16):2250-94.
6. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167(4):580-6.
7. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S-12S.
8. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6(4):750-6.
9. Hinderliter AL, Willis PW 4th, Long WA, Clarke WR, Ralph D, Caldwell EJ, et al. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol 2003;91(8):1033-1037, A9.
10. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronz waer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28(10):1250-1257.
11. Karamanoglu M, McGoon M, Frantz RP, Benza RL, Bourge RC, Barst RJ, et al. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest 2007;132(1):37-43.
12. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114(13):1417-31.
13. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higen bottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25(24): 2243-78.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327(2):76-81.
15. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111(23):3105-11.
16. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131(6):1917-28.
17. Bocchi EA, Bacal F, Auler Junior JO, Carmone MJ, Bellotti G, Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994;74(1):70-2.
18. Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004;98(3):225-34.
19. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34(4):1184-7.
20. Deng H, Wu J, So SP, Ruan KH. Identification of the residues in the helix F/G loop important to catalytic function of membrane-bound prostacyclin synthase. Biochemistry 2003; 42(19):5609-17.
21. Dogne JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004;11(10):1223-41.
22. Ruan KH. Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway. Mini Rev Med Chem 2004;4(6):639-47.
23. Lin Y, Wu KK, Ruan KH. Characterization of the secondary structure and membrane interaction of the putative membrane anchor domains of prostaglandin I2 synthase and cytochrome P450 2C1. Arch Biochem Biophys 1998;352(1):78-84.
24. Lin YZ, Deng H, Ruan KH. Topology of catalytic portion of prostaglandin I(2) synthase: identification by molecular modeling-guided site-specific antibodies. Arch Biochem Biophys 2000;379(2):188-97.
25. Ren Y, Walker C, Ruan KH, Kulmacz RJ. Examination of prostaglandin H synthase-1 topology in the endoplasmic reticulum membrane. Adv Exp Med Biol 1997;400A:171-5.
26. Ruan KH, Deng H, Wu J, So SP. The N-terminal membrane anchor domain of the membrane-bound prostacyclin synthase involved in the substrate presentation of the coupling reaction with cyclooxygenase. Arch Biochem Biophys 2005;435(2): 372-81.
27. Ruan KH, Dogne JM. Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. Curr Pharm Des 2006;12(8):925-41.
28. Ruan KH, So SP, Zheng W, Wu J, Li D, Kung J. Solution structure and topology of the N-terminal membrane anchor domain of a microsomal cytochrome P450: prostaglandin I2 synthase. Biochem J 2002;368(Pt 3):721-8.
29. Ruan KH, Wu J, Cervantes V. Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosyn thesis of prostacyclin. Biochemistry 2008;47(2):680-8.
30. Shyue SK, Ruan KH, Wang LH, Wu KK. Prostacyclin synthase active sites. Identification by molecular modeling-guided site-directed mutagenesis. J Biol Chem 1997;272(6):3657-62.
31. Wang LH, Matijevic-Aleksic N, Hsu PY, Ruan KH, Wu KK, Kulmacz RJ. Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis. J Biol Chem 1996;271(33):19970-5.
32. Wu J, So SP, Ruan KH. Determination of the membrane contact residues and solution structure of the helix F/G loop of= prostaglandin I2 synthase. Arch Biochem Biophys 2003;411 (1):27-35.
33. Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist an antagonist binding sites. Mol Pharmacol 1993;44(5):934-9.
34. Ni F, So SP, Cervantes V, Ruan KH. A profile of the residues in the second extracellular loop that are critical for ligand recognition of human prostacyclin receptor. FEBS J 2008;275 (1):128-37.
35. Ruan CH, Wu J, Ruan KH. A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor. BMC Biochem 2005;6:23.
36. Ruan KH, Wu J, So SP, Jenkins LA. Evidence of the residues involved in ligand recognition in the second extracellular loop of the prostacyclin receptor characterized by high resolution 2D NMR techniques. Arch Biochem Biophys 2003;418(1): 25-33.
37. Zhang L, Bastepe M, Juppner H, Ruan KH. Characterization of the molecular mechanisms of the coupling between intra-cellular loops of prostacyclin receptor with the C-terminal do-main of the Galphas protein in human coronary artery smooth muscle cells. Arch Biochem Biophys 2006;454(1):80-8.
38. Zhang L, Huang G, Wu J, Ruan KH. A profile of the residues in the first intracellular loop critical for Gs-mediated signaling of human prostacyclin receptor characterized by an integrative approach of NMR-experiment and mutagenesis. Biochemistry 2005;44(34):11389-401.
39. Zhang L, Wu J, Ruan KH. Solution structure of the first intracellular loop of prostacyclin receptor and implication of its interaction with the C-terminal segment of G alpha s protein. Biochemistry 2006;45(6):1734-44.
40. Miyaji K, Matsubara H. Continuous intravenous prostacyclin therapy [in Japanese]. Nippon Rinsho 2008;66(11):2139-44.
41. Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172(12): 1586-9.
42. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, Simonneau G. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126(2):420-7.
43. Skoro-Sajer N, Lang I. The role of treprostinil in the man agement of pulmonary hypertension. Am J Cardiovasc Drugs 2008;8(4):213-7.
44. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009;22(1):50-6.
45. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 2009;37(3):980-6.
46. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 2005;172(3):358-63.
47. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004;94(8):1101-8.
48. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Ilo-prost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33(6):1354-60.
49. Pullamsetti S, Krick S, Yilmaz H, Ghofrani HA, Schudt C, Weissmann N, et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005;6:128.
50. Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26(11):1079-83.
51. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial [published errata appear in Ann Intern Med 2009;150(1):63 and Ann Intern Med 2009;151(6):435]. Ann Intern Med 2008;149(8):521-30.
52. Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008;134(1):139-45.
53. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled ilo-prost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174(11):1257-63.
54. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28(4):691-4.
55. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496-502.
56. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension [published erratum appears in J Am Coll Cardiol 2003;42(3):591]. J Am Coll Cardiol 2003;41(12):2119-25.
57. Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007;71(11):1829-31.
58. Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, Banat GA, et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 2008;178(2):188-96.
59. Camacho M, Rodriguez C, Salazar J, Martinez-Gonzalez J, Ribalta J, Escudero JR, et al. Retinoic acid induces PGI synthase expression in human endothelial cells. J Lipid Res 2008; 49(8):1707-14.
60. Chen SJ, Wang YB, Chen O, Zhu XB, Ma Y. Effect of p21 gene transfection mediated by replication deficient adenovirus on the pulmonary hypertensive rat model [in Chinese]. Zhonghua Er Ke Za Zhi 2008;46(2):139-42.
61. Kawakami T, Kanazawa H, Satoh T, Ieda M, Ieda Y, Kimura K, et al. AAV-PGIS gene transfer improves hypoxia-induced pulmonary hypertension in mice. Biochem Biophys Res Commun 2007;363(3):656-61.
62. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, et al. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension 2007;50(3):531-6.
63. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 2000;102(16):2005-10.
64. Tahara N, Kai H, Niiyama H, Mori T, Sugi Y, Takayama N, et al. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 2004;15(12):1270-8. Volume 37, Number 4, 2010
65. Harada-Shiba M, Takamisawa I, Miyata K, Ishii T, Nishiyama N, Itaka K, et al. Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats. Mol Ther 2009;17(7): 1180-6.
66. Akagi D, Oba M, Koyama H, Nishiyama N, Fukushima S, Miyata T, et al. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther 2007;14(13):1029-38.
67. Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S, et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2008;177(2):219-26.
68. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001;104(18):2242-8.
69. Gong F, Tang H, Lin Y, Gu W, Wang W, Kang M. Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr Int 2005;47(3):242-7.
70. Ono M, Sawa Y, Fukushima N, Suhara H, Nakamura T, Yokoyama C, et al. Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats. Eur J Cardiothorac Surg 2004;26(6):1092-7.
71. Ishii M, Numaguchi Y, Okumura K, Kubota R, Ma X, Murakami R, et al. Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. Atherosclerosis 2009;206(1):109-18.
72. Campbell AI, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999;21(5): 567-75.
73. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96(4):442-50.
74. Marsboom G, Pokreisz P, Gheysens O, Vermeersch P, Gillijns H, Pellens M, et al. Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells 2008;26(4):1017-26.
75. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T,Fukuyama N, et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003;108(7):889-95.
76. Di Stefano R, Barsotti MC, Melillo E, Iorio M, Santoni T, Armani C, et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008;100(5):871-7.
77. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007;115(15): 2022-32.
78. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006;113(11): 1442-50.
79. Ruan KH, inventor; Board of Regents of the University of Texas System, assignee. Hybrid protein that converts ara chidonic acid into prostacyclin. United States patent article WO/2007/104000. 2007 Sep 13.
80. Ruan KH, Deng H, So SP. Engineering of a protein with cyclooxygenase and prostacyclin synthase activities that converts arachidonic acid to prostacyclin. Biochemistry 2006;45(47): 14003-11.
81. Ruan KH, So SP, Cervantes V, Wu H, Wijaya C, Jentzen RR. An active triple-catalytic hybrid enzyme engineered by linking cyclo oxygenase isoform-1 to prostacyclin synthase that can constantly biosynthesize prostacyclin, the vascular protector. FEBS J 2008;275(23):5820-9.
82. Ruan KH, So SP, Wu H, Cervantes V. Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potential. Arch Biochem Biophys 2008;480(1):41-50.
83. Yuan J, Westney OL, Ruan KH, Wang R. A new strategy, SuperEnzyme gene therapy in penile rehabilitation. J Sex Med 2009;6 Suppl 3:328-333.
84. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, Kuwabara K. 2-[4-[(5,6-diphenylpyrazin-2-yl)(iso-propyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-1188.
85. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino] butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl) amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008;326(3):691-699.
86. Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, et al. Iloprost-induced de-sensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4.